Cargando…
Association of creatine kinase and skin toxicity in phase I trials of anticancer agents
BACKGROUND: We investigated the association between skin rash and plasma creatine kinase (CK) levels in oncology phase I trials. METHODS: We analysed data from 295 patients treated at our institution within 25 phase I trials which included CK measurements in the protocol. Trials involved drugs targe...
Autores principales: | Moreno Garcia, V, Thavasu, P, Blanco Codesido, M, Molife, L R, Vitfell Pedersen, J, Puglisi, M, Basu, B, Shah, K, Iqbal, J, de Bono, J S, Kaye, S B, Banerji, U |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3504946/ https://www.ncbi.nlm.nih.gov/pubmed/23099802 http://dx.doi.org/10.1038/bjc.2012.482 |
Ejemplares similares
-
Creatinine Clearance Is Associated with Toxicity from Molecularly Targeted Agents in Phase I Trials
por: Basu, B., et al.
Publicado: (2012) -
Titration of signalling output: insights into clinical combinations of MEK and AKT inhibitors
por: Stewart, A., et al.
Publicado: (2015) -
Complications of hyperglycaemia with PI3K–AKT–mTOR inhibitors in patients with advanced solid tumours on Phase I clinical trials
por: Geuna, E, et al.
Publicado: (2015) -
Phase I trial outcomes in older patients with advanced solid tumours
por: Khan, K H, et al.
Publicado: (2016) -
Clinical benefit in Phase-I trials of novel molecularly targeted agents: does dose matter?
por: Postel-Vinay, S, et al.
Publicado: (2009)